CIK 0001048477
- Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680397820
- Phone
- +1 415-506-6700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,163,748
- in 1 filing
Net −$1,163,748. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-09 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale 10b5-1 | −13,626 | $94.22 | $1.3M | 442,587 |
| 2023-05-09 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale 10b5-1 | −14,964 | $95.49 | $1.4M | 427,623 |
| 2023-05-09 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale 10b5-1 | −1,410 | $95.90 | $135K | 426,213 |
| 2023-05-09 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −30,000 | 99,130 | ||
| 2023-05-09 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −30,000 | 69,130 | ||
| 2023-05-04 | Guyer Charles Greg EVP, Chief Technical Officer | Shares withheld for taxes | −4,302 | $95.45 | $411K | 45,401 |
| 2023-04-28 | FUCHS HENRY J President, Worldwide R&D | Grant or award | +317 | $66.88 | $21K | 176,504 |
| 2023-04-28 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Grant or award 10b5-1 | +318 | $66.88 | $21K | 65,804 |
| 2023-04-28 | Davis George Eric EVP, Chief Legal Officer | Grant or award | +317 | $66.88 | $21K | 80,684 |
| 2023-04-28 | BIENAIME JEAN JACQUES Chief Executive Officer | Grant or award 10b5-1 | +317 | $66.88 | $21K | 426,213 |
| 2023-04-28 | Guyer Charles Greg EVP, Chief Technical Officer | Grant or award | +239 | $66.88 | $16K | 49,703 |
| 2023-04-10 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion 10b5-1 | +10,000 | $67.81 | $678K | 435,896 |
| 2023-04-10 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale 10b5-1 | −10,000 | $99.56 | $996K | 425,896 |
| 2023-04-10 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −10,000 | 129,130 | ||
| 2023-04-06 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion 10b5-1 | +10,000 | $67.81 | $678K | 435,896 |
| 2023-04-06 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale 10b5-1 | −10,000 | $96.13 | $961K | 425,896 |
| 2023-04-06 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −10,000 | 139,130 | ||
| 2023-04-03 | LAWLIS V BRYAN Director | Exercise or conversion 10b5-1 | +8,500 | $67.81 | $576K | 37,450 |
| 2023-04-03 | LAWLIS V BRYAN Director | Sale 10b5-1 | −8,500 | $97.09 | $825K | 28,950 |
| 2023-04-03 | LAWLIS V BRYAN Director | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −8,500 | 0 |
Page 15 of 23 · 450 trades